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ALP        alkaline phosphatase 
CLEIA       chemiluminescent enzyme immunoassay 
CPE         cytopathic effect 
E            estradiol 
EC50         50% effective concentration 
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EHV-3       equine herpesvirus 3 
EIA          enzyme immunoassay 
FCS         fetal calf serum 
FHK         fetal horse kidney 
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FIA          fluoroimmunoassay 
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i.m.          intramuscular 
ISBC        the International Stud Book Committee 
JAIRS       Japan Association for International Racing and Stud Book 
LH          luteinizing hormone 
MEM        minimum essential medium 
P            progesterone 
PBS         phosphate buffered saline  
PCR         Polymerase chain reaction 
PGF2α       prostaglandin F2α 
RIA          radioimmunoassay 
SEM         standard error of the mean 
SN           serum neutralization 
STD         sexually transmitted disease 
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PREFACE 
Thoroughbred has been bred for racing from early 18 centuries in the world. 
In Japan, Thoroughbred breeding started in 1907 and it is the most popular breed 
in horses in the present day. In the report of 2014, there are 40,794 Thoroughbreds 
among 73,977 total horse population in Japan that includes 5,880 heavy breeds, 
672 ponies, 1,817 native horses, 9,081 fattening horses and 15,475 horses for riding 
[1]. More than 6,000 Thoroughbreds are born every year [1]. The pedigree of 
Thoroughbreds is well managed in each country. In Japan, it is managed by Japan 
Association for International Racing and Stud Book (JAIRS), Japanese 
representative of the International Stud Book Committee (ISBC), and all 
Thoroughbred mares and stallions for breeding are registered with JAIRS. In 2017, 
10,320 mares and 267 stallions are registered as broodmare and sire, of those, 
97.5% of mares and 93.6% of stallions are managed in Iburi and Hidaka areas in 
Hokkaido, Japan.  
Management of stallions in good health and reproductive conditions and 
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carrying out mating safely are required for stud. Diagnosis of the estrus condition 
of mares and diagnosis of reproductive abnormality in stallions are usually done 
based on clinical findings, but often need special examinations that include 
evaluation of endocrine status of mares and stallions. However, hormone assays 
are expensive and time-consuming. Further, there were no commercially available 
sex steroid hormone assay systems that is verified for horse use. Therefore, in 
Chapter I, application of a hormone assay system developed for human use, that 
is inexpensive and gives results in short time, was verified for evaluation of the 
reproductive conditions in mares and stallions.  
In Thoroughbred horse racing industry, all horses are bred by natural 
service since the rule set by ISBC [108]. However, mares and stallions for breeding 
are selected by their race results and pedigree, not by their fertility. Therefore, 
some stallions are found to be infertile after registration to JAIRS as sire. 
Sometimes there are stallions with cryptorchidism, without testes in scrotum, are 
diagnosed by evaluation of testosterone (T) concentrations after human chorionic 
gonadotrophin (hCG) administration. On the other hands, some stallion shows low 
libido since young males are managed separately from females and trained not to 
show an interest to females during the training period for racing [57]. This may 
make some stallions hesitate to mount mares in estrus when they are introduced 
to breeding studs. Thus, differential diagnosis is needed to segregate causes of 
mating difficulty due to these mental reasons from physical reasons and functional 
abnormalities of genital organs. Hormonal evaluation is again useful for this usage.  
For female aspects, there are also some reproductive problems. Horses are 
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long-day breeder and breeding season is spring and summer [82]. However, 
producers often prefer to start breeding early months (February ~ March) of the 
year since foals that were born early months of the year are large in body size and 
sell better than the smaller foals that are born in late months of the year. For early 
breeding, the length of day-time is controlled by artificial light and some hormonal 
products are used to activate the estrus cycle in mares [14]. Hormone assays are 
useful tools to monitor ovarian activities especially during early months of the year. 
Further, most farms managing mares do not have a male horse as a teaser and 
timing of mating is usually diagnosed by rectal palpation and ultrasonography. 
Consequently, some mares with poor estrus conditions, too early or too late for 
breeding, are sent to breeding studs. Again, hormone assays are helpful to evaluate 
the ovarian activities of mares.  
Some automated benchtop analyzers for measuring steroid hormone 
concentrations are available for human. One of those system, a chemiluminescent 
enzyme immunoassay (CLEIA) system (PATHFAST, LSI Medicine Corporation, 
Tokyo, Japan) was developed for measurement of hormonal concentrations in 
human [18, 52, 91]. This system can measure sex steroid hormones in serum and 
whole blood without extraction within 30 minutes. However, binding proteins and 
other factors in sera often interfere in immunoassay systems; thus, an 
immunoassay system developed for one species needs to be verified for other 
species and sometimes for other applications [20]. There is no report for verification 
to use these systems for horses.  
In chapter II, two clinical cases of equine coital exanthema (ECE), a 
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sexually transmitted disease (STD) caused by equine herpesvirus 3 (EHV-3), are 
described together with a sero-epidemiological study of ECE. Prevention and 
control of STD is another important aspect of stud management. The laws (i.e. Act 
on Domestic Animal Infectious Diseases Control and Act on Improvement and 
Increased Production of Livestock) defined some diseases including equine 
infectious anemia, equine paratyphoid, contagious equine metritis and equine 
rhinopneumonitis, that must be controlled by culling or reporting to the local 
authorities. Recently, ECE caused by EHV-3, a disease not in the lists of diseases 
of the laws diagnosed in our stud sporadically. There had been no epidemiological 
study on ECE in Japan. Stallions affected by ECE cannot mate with mares for pain 
and the risk of transmission [2, 6, 9, 29]. Thus, ECE causes a serious economic loss 
of breeding studs and farms. Acyclovir, an anti-herpesvirus agent, has been shown 
an effective to ECE [6, 19, 81]. Valacyclovir, a prodrug of acyclovir, has been used 
for treatment of equine rhinopneumonitis caused by equine herpesvirus 1 and 
shown its effectiveness [32] partly because due to, a longer half-life in circulation 
[33].  
This study is composed of two chapters. In Chapter I, the application of the 
CLEIA system for sex steroid hormone assays in horses was verified. In Chapter 
II, the clinical cases of ECE were investigated and a sero-epidemiological survey 
for ECE was conducted in Japan.  
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Section 1. Progesterone 
1.1.1. Introduction 
The physiological function of progesterone (P) is to prepare the uterine 
endometrium for implantation of embryos [37, 44] and maintain uterine conditions 
for the growing fetus during pregnancy in females [40]. Therefore, measurement 
of P is useful for detecting luteal function [3] and placental function in cyclic and 
pregnant mares. There is a need to rapidly measure P in equine clinical sites for 
early diagnosis of luteal activity during the estrous cycle. It is also important to 
know the levels of circulating P of estrous mares before covering with stallions to 
get normal fertilization and growing embryos.    
Chemiluminescent enzyme immunoassay (CLEIA) system (PATHFAST, 
LSI Medience Corporation, Tokyo, Japan) was developed for human use as a small, 
automated, bench top analyzer [18, 52, 91]. This system can measure sex steroid 
hormones in sera and whole blood within 30 minutes (min) without extraction 
using a dedicated cartridge. All procedures are done automatically and it does not 
need to set up standard curve on each measurement. The cost of using the CLEIA 
system is equal to or lower than that of the existing radioimmunoassay (RIA), the 
enzyme immunoassay (EIA) and the fluoroimmunoassay (FIA). Unlike 
proteinaceous gonadotropins, structures of steroid hormones are not different 
between species. However, binding proteins and other factors in sera often 
interfere in immunoassay systems; thus, an immunoassay system developed for 
one species needs to be verified for other species and, sometimes, for other 
applications [20].  
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The purpose of this study was to evaluate the validity of CLEIA system by 
comparing the P concentrations measured by this system with those measured by 
RIA and EIA which have been used in mares. Then, P measurement by the CLEIA 
system using whole blood as a sample was verified for field use.  
 
1.1.2. Materials and Methods 
Animals 
Mares in Iburi area, Hokkaido, Japan, kept under natural conditions were 
used for measuring circulating P. Three Thoroughbred mares (4-11 years old) were 
used for comparison of P concentrations measured by CLEIA system and RIA, and 
in whole blood and serum. Four Thoroughbred mares (4-11 years old) were used 
for comparison of P concentrations measured by CLEIA system and EIA. All mares 
were subjected to daily ultrasonographic investigation using a B-mode scanner 
(ALOKA SSD-620, Hitachi Medical Corporation, Tokyo, Japan), and their ovaries 
were monitored. After confirming the existence of a corpus luteum, all mares were 
administrated a single intramuscular (i.m.) injection of 1 ml (250 µg) of a synthetic 
analogue of prostaglandin F2α (PGF2α, Estrumate, Intervet, Tokyo, Japan). Blood 
samples were then collected from the jugular vein at 0, 15, 30 and 45 min, at one-
hour (hr) intervals until 24 hr and at 48 hr via a catheter in the jugular vein for 
comparison of P concentrations measured by CLEIA system and RIA, and in whole 
blood and serum (n = 88). Blood samples were collected with the same way until 
24 hr for comparison of P concentrations measured by CLEIA system and EIA (n = 
112).  
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Sample preparation and experiments 
For collection of serum samples, whole blood was drawn from the jugular 
vein of the mares into a plain blood collection tube. Serum was separated by 
centrifugation at 1,700 ×g for 10 min. For the correlation experiments between 
whole blood and serum, whole blood samples were collected from the jugular vein 
into heparin sodium-loaded tubes. Concentrations of P in all samples were 
measured by CLEIA system. Serum samples were used for comparisons between 
CLEIA system and RIA or EIA. All procedures were carried out in accordance with 
the guidelines established by the institutional Animal Care and Use Committee of 
Tokyo University of Agriculture and Technology. 
 
Hormone assay  
1) CLEIA system 
P concentrations in serum and whole blood were measured by a CLEIA 
system that was developed and verified for human sera, plasma, and heparinized 
whole blood. 100 µl of either serum or whole blood was applied to a reagent 
cartridge for the P assay (PF0181-K, LSI Medience Corporation) without 
extraction. The reagent cartridge was set into a CLEIA analyzer to run assays. All 
reagents were contained in the cartridge, and all of the procedures of the assay 
were performed inside it. The CLEIA system is based on a one-step competitive 
immunoassay system method. Using this procedure, samples were first mixed with 
an alkaline phosphatase (ALP)-labeled antibody and a magnetic latex reagent. 
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Magtration○R  was then used to remove excess reagents and residual materials not 
bound to the magnetic latex. A chemiluminescent substrate (CDP-Star○R ) was 
added, and luminescence was emitted upon binding to the ALP. Luminescence was 
then measured and hormonal concentrations were determined. The assay range of 
CLEIA system was 0.2-40.0 ng/ml. Based on the manufacturer’s catalogue, the 
intra-assay coefficients of variance were determined to be 3.61%-10.23% for serum 
and 7.1% -16.7% for whole blood samples. 
 
2) RIA and EIA 
Serum concentrations of P were determined by a double-antibody RIA 
system using 125I-labeled radioligands as described previously [99]. 500 µl of 
standard and sample were extracted for P once with 2 ml of ether. After extraction, 
300 µl of phosphatase buffered saline (PBS, 0.05M) containing 1% bovine serum 
albumin (BSA) was added. 100 µl of standard or sample was mixed with 100 µl of 
anti-progesterone (GDN337, provided by Dr. G. D. Niswender, Animal 
Reproduction and Biotechnology, Colorado State University, Fort Collins, Co, 
U.S.A.) in PBS (0.05M) containing normal sheep serum and EDTA (0.05M). And 
then, 100 µl of 125I-labelled radioligands in PBS (0.05M) containing 1% BSA was 
added and incubated at 4°C for 24 hr. After incubation, 100 µl of anti-sheep gamma 
globulin diluted with PBS (0.05M) containing 5% polyethylene glycol was added 
and incubated at 4°C for 24hr. After that, standard and samples were centrifuged 
at 1700 ×g for 30 min at 4°C. Supernatant was removed and radioactivity was 
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counted by gamma-counter. The assay results were obtained within 48 hr. The 
intra- and inter-assay coefficients of variance were 6.3% and 7.2%. 
Serum concentrations of P were also determined by a double-antibody EIA 
system without ether extraction as described previously [70]. To prepare immuno 
plate, 100 µl of anti-rabbit-IgG (H+L)-goat (Jackson ImmunoResearch; 111-005-
003) diluted to 2 µg/ml was added to 96 well immuno plate (Nunc; 442404) and the 
plate was incubated at room temperature for 24 hr. Anti-rabbit-IgG not combined 
to plate was removed and 250 µg of assay buffer including 0.1% of BSA was added. 
The plate was incubated at room temperature for 30 min and this plate was stored 
at 4°C until assay. For measurement of P concentration, 20 µg of standard for P 
and samples were added to each well. 100 µl of anti-progesterone rabbit serum 
diluted 100,000 times and 100 µl of P labeled with Horseradish Peroxydase were 
added and the plate was incubated at 4°C overnight. After incubation, supernatant 
was removed and the plate was washed with 0.05% of Tween 80 for 4 times. 150 
µg of substrate buffer was added and incubated at 35°C for 40 min. After 
incubation, 50µg of 4NH2SO4 was added and absorbance at 450 nm was measured 
(BIORAD Model 450 Microplate Reader). The assay results were obtained within 
48 hr. The intra- and inter-assay coefficients of variance were 6.3% and 10.6%. 
 
Statistics 
Pearson’s r was calculated to find correlation between variables using the 
GraphPad Prism 5 software for Windows (GraphPad Software, San Diego, CA, 
U.S.A.). 
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1.1.3. Results 
The concentrations of P in serum samples measured by CLEIA system were 
compared with those measured by RIA (Fig. 1.1.1). The results obtained by CLEIA 
system showed a significant correlation with those obtained by RIA (r = 0.9654, p 
< 0.0001, n = 88). The pattern of circulating P in serum obtained by CLEIA system 
showed excellent correlation with that obtained by RIA, although the values 
measured by CLEIA system were about two times higher than those measured by 
RIA (Fig. 1.1.2). 
In addition, the concentrations of P in serum samples measured by CLEIA 
system were also compared with those measured by EIA (Figs. 1.1.3 and 1.1.4). A 
high positive correlation was observed between the concentrations of P measured 
by CLEIA system and EIA (Fig. 1.1.3, r = 0.9323, p < 0.0001, n = 112). The 
concentrations of P in the serum of the four mares measured by CLEIA system 
showed a parallel pattern to those measured by EIA (Fig. 1.1.4). 
The correlation of concentrations of P in whole blood and serum samples 
measured by CLEIA system was examined (Fig. 1.1.5). There was excellent 
positive correlation between whole blood and serum samples (r = 0.9672, p < 0.0001, 
n = 88). 
The patterns of circulating P in whole blood and serum measured by CLEIA 
system were compared in three mares after the single injection of PGF2α (Fig. 
1.1.6). Significant correlation of concentrations of P in whole blood and serum 
samples was observed in all mares. Circulating P in whole blood and serum 
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samples declined rapidly and had declined by about 50% at 2 hr after the PGF2α 
injection; the levels reached the basal levels in whole blood (a, 1.07 ng/ml; b, 1.69 
ng/ml; c, 1.66 ng/ml) and serum (a, 0.84 ng/ml; b, 1.33 ng/ml; c, 1.36 ng/ml) at 24 
hr after injection. A further decline in concentrations of P was observed in both 
whole blood and serum samples at 48 hr after injection. 
  
1.1.4. Discussion 
The present study evaluated the validity of rapid measurement of equine P 
using a new practical assay system, CLEIA system. 
In the experiment in which CLEIA system was compared with RIA and EIA, 
CLEIA system showed excellent correlation, with correlation coefficients of 0.9654 
(n = 88) and 0.9323 (n = 112). In the present study, the concentrations of P in serum 
of mares at luteolysis measured by CLEIA system were about two times higher 
than those measured by RIA. Although the exact reason for this is not clear at the 
present time, it seems to be related to the different methods of sample preparation, 
such as extraction of steroid hormones using ether in RIA. In addition, the different 
cross-reactivities of the anti-P sera used in CLEIA system and RIA may affect 
estimation of the concentrations of P. It does not seem that the difference of the 
values between two methods reduces the utility of CLEIA system for diagnosis 
whether the mare coming to stud is in estrus or in luteal phase.   
Measurements of P in whole blood and serum samples of mares showed 
excellent correlation in the present study, indicating that concentrations of P can 
15 
 
be measured in whole blood as well as serum samples in mares using CLEIA 
system.  
The parallelism of the pattern of P levels in serum samples measured by 
CLEIA system and RIA was confirmed. This is also true for CLEIA system and EIA. 
These results clearly demonstrated that CLEIA system correctly monitored the 
physiological changes in circulating P during induced luteolysis in cyclic mares. 
Physiological changes in circulating P during the process of induced luteolysis in 
mares were examined using CLEIA system. Measurement of P in whole blood and 
serum samples showed excellent parallel patterns, indicating that CLEIA system 
can be used to measure circulating P in whole blood in mares. 
In clinical application of P measurement to diagnosis of reproductive 
condition in the equine clinic, there is a need for a rapid measurement system in 
addition to a measurement system that uses whole blood samples. In the present 
study, the concentrations of P in both whole blood and serum samples could be 
measured by CLEIA system within 30 min without ether extraction. In conclusion, 
CLEIA system is useful in the equine hospital as an accurate diagnostic tool for 
rapid assay of P [105]. 
 
 
 
 
 
 
16 
 
 
 
 
 
 
 
 
 
 
 
0 5 10 15
0
5
10
15
r=0.9654
n=88
CLEIA (ng/ml)
R
IA
 (n
g/
m
l)
 
Figure 1.1.1 Correlation plots between progesterone (P) measured by a 
chemiluminescent enzyme immunoassay (CLEIA) and a radioimmunoassay (RIA) 
in serum samples.  
  P concentrations measured by two methods were strongly correlated (r = 
0.9654). 
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Figure 1.1.2 Changes in circulating progesterone (P) in serum samples of three 
mares (a, b, c) after administration of a single i.m. injection of prostaglandin F2α.  
 P concentrations were assayed by a chemiluminescent enzyme 
immunoassay (CLEIA) (●) and a radioimmunoassay (RIA) (○).  
 
 
 
 
 
18 
 
 
0 10 20 30
0
10
20
30
r=0.9323
n=112
CLEIA (ng/ml)
EI
A 
(n
g/
m
l)
 
Figure 1.1.3 Correlation plots between progesterone (P) measured by a 
chemiluminescent enzyme immunoassay (CLEIA) and an enzyme immunoassay 
(EIA) in serum samples.  
P concentrations measured by two methods were strongly correlated (r = 
0.9323). 
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Figure 1.1.4 Changes in circulating progesterone (P) in serum samples of four 
mares (a, b, c, d) after administration of a single i.m. injection of prostaglandin 
F2α.  
P concentrations were assayed by a chemiluminescent enzyme 
immunoassay (CLEIA) (●) and an enzyme immunoassay (EIA) (○). 
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Figure 1.1.5 Correlation plots between progesterone (P) measured by a 
chemiluminescent enzyme immunoassay in whole blood and serum samples of 
mares.  
 P concentrations in whole blood and serum were strongly correlated (r = 
0.9672). 
 
 
 
 
 
 
 
 
21 
 
0 30
0
5
10
15
48
Whole blood
Serum
(a)
1 4 8 12 16 20 24
Pr
og
es
te
ro
ne
 (n
g/
m
l)
030
0
5
10
15
48
(c)
1 4 8 12 16 20 24
Pr
og
es
te
ro
ne
 (n
g/
m
l)
030
0
5
10
15
48
(b)
1 4 8 12 16 20 24
Pr
og
es
te
ro
ne
 (n
g/
m
l)
Minutes Hours
Time after administration
Minutes Hours
Time after administration
 
Figure 1.1.6 Changes in circulating progesterone (P) in whole blood (○) and serum 
samples (●) of three mares (a, b, c).  
P concentrations were assayed by a chemiluminescent enzyme 
immunoassay after  
administration of a single i.m. injection of prostaglandin F2α. 
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Section 2. Estradiol 
1.2.1. Introduction 
Estradiol (E) is secreted by the granulosa cells of the mature antral follicle 
in mares [22, 54, 58, 63, 64, 68]. It induces estrus and prepares the uterus for 
fertilization and implantation by promoting endometrial growth, development of 
the uterine gland, and secretion of uterine and vaginal mucus [54]. The 
physiological function of E is to induce embryo implantation in the uterus and 
maintain uterine conditions for the growing fetus during pregnancy [41, 74, 94–
97]. Therefore, measurement of E is useful for detecting follicular and placental 
function in cyclic and pregnant mares. Circulating E has routinely been measured 
by RIA, EIA or FIA using plasma or serum samples extracted for E in equine clinics. 
Although these assays have sufficient sensitivity, accuracy, and simplicity, a period 
of one or two days is required to get their results. Therefore, there is a need for a 
rapid measurement technique that can be performed at equine clinics for early 
diagnosis. 
The purpose of this study was to evaluate the validity of CLEIA system, as 
an accurate diagnostic tool for a rapid measurement of circulating E in mares using 
serum and whole blood samples without extraction in equine clinics. 
 
1.2.2. Materials and Methods 
Animals 
129 thoroughbred mares (2-22 years of age) housed under natural 
conditions in Hokkaido, Japan were used for measuring the levels of circulating E.  
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Sample preparation and experiments 
For the experiments determining the correlation between the results of 
CLEIA system and FIA, two pregnant mares, 4 and 15 years of age, were used. 
Serum samples were collected monthly from the jugular vein into commercially 
supplied plastic tubes at the day of copulation and the day of delivery (n = 27). The 
concentrations of E in all samples were measured by CLEIA and FIA. 
For determining the correlation between the results for whole blood and 
serum, five pregnant mares, 8-19 years of age, were used. Whole blood samples 
were collected weekly from the jugular vein into heparin sodium-loaded tubes 
during day 233 of pregnancy and the day of delivery (n = 50). For serum sample 
collection, whole blood was drawn from the jugular vein of the same mares into 
plain blood collection tubes. Serum was separated by centrifugation at 1,700 ×g for 
10 min. The concentrations of E in all samples were measured by CLEIA system. 
For evaluating the pattern of circulating E during gestation in mares, 122 
pregnant mares, ranging from 2-22 years of age, were used. Serum samples were 
collected during gestation from the jugular vein into commercially supplied plastic 
tubes. All mares delivered normally. The E concentrations in all samples were 
measured by CLEIA system. All procedures were carried out in accordance with 
the guidelines established by the institutional Animal Care and Use Committee of 
Tokyo University of Agriculture and Technology. 
 
Hormone assay  
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1) CLEIA system 
The concentrations of E in whole blood and serum samples were 
determined using the CLEIA system with the reagent for E (PF0171-K, LSI 
Medience Corporation) as described in section 1. The assay range of E by CLEIA 
system was between 20 and 2,000 pg/ml. The intra-assay coefficients of variance 
were 6.3% -12.9% for serum and 7.0%-12.4% for whole blood samples. 
 
2) FIA  
Serum concentrations of E were measured by using a time-resolved FIA kit 
(DELFIA, PerkinElmer, Waltham, MA, U.S.A.) as described previously [28, 48, 68] . 
Samples were added to a plate coated with an anti-rabbit IgG. After incubation 
and washing, a europium-labeled E and anti-E IgG was added and they were 
incubated. Enhancement solution was added and fluorescence was measured by a 
time-resolved fluorometer (ARVO X4, PerkinElmer, MA, U.S.A.). This system uses 
serum or plasma without extraction and the assay takes approximately 3 hr. The 
measurement was performed without extraction. The intra- and inter-assay 
coefficients of variation were 5.0% and 5.1%, respectively.  
 
Statistics 
Pearson’s r and P value were calculated as described in section 1.  
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1.2.3. Results 
The pattern of circulating E in the serum of two pregnant mares as 
measured by CLEIA system and FIA is shown in Fig. 1.2.1 as a sequential pattern 
throughout gestation. In Fig. 1.2.1a, serum concentrations of E measured by 
CLEIA system and FIA began to increase from 4 months after copulation, peaked 
at 8 months after copulation, and abruptly declined to the term. In Fig. 1.2.1b, the 
serum E concentrations measured by CLEIA system and FIA also began to increase 
from 5 months after copulation, peaked at 8 and 9 months after copulation followed 
by an abrupt decline to the term. In panel a, the values measured by CLEIA system 
tended to be high compared with those measured by FIA during the increasing 
phase between 4 and 8 months after copulation. This was also the same to panel b. 
The concentrations of E in serum samples as measured by CLEIA system were 
compared with those measured by FIA (Fig. 1.2.2). The results obtained by CLEIA 
system showed a significant correlation with those measured by FIA (r = 0.9521, P 
< 0.0001, n = 27).  
The correlation of E concentrations in whole blood and serum samples from 
pregnant mares measured by CLEIA system is shown in Fig. 1.2.3. There was a 
significant positive correlation between the concentrations in whole blood and 
serum samples (r = 0.9341, P < 0.0001, n = 50). 
To monitor physiological changes, the concentrations of E in serum samples 
obtained throughout the gestation period were measured by CLEIA system (Fig. 
1.2.4). Circulating E began to increase in 15 weeks after copulation, and linearly 
increased until 31 weeks after copulation. High levels of serum E were maintained 
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between 30 and 43 weeks after copulation, followed by an abrupt decline (Fig. 
1.2.4).  
 
1.2.4. Discussion 
The present study evaluated the validity of the rapid measurement of 
equine E using the new practical assay system, CLEIA system. 
In the study of the method comparison of CLEIA system to FIA showed a 
positive correlation significantly (r = 0.9521, P < 0.0001, n = 27). In the present 
study, serum concentrations of E as measured by CLEIA system showed a parallel 
pattern to those measured by FIA, even though the values measured by CLEIA 
system tended to be higher than those measured by FIA during mid-gestation. 
Although the exact reason for this is not presently clear, the difference could be 
attributed to the differing cross reactivity of the anti-estradiol antibodies used in 
CLEIA system and FIA.  
In the present study, E concentrations in whole blood and serum of mares 
showed excellent positive correlation, indicating that E concentrations can be 
measured in whole blood as well as in serum samples using CLEIA system.  
In the present study, the physiological changes in circulating E levels 
during the gestation in mares were further examined using CLEIA system. The 
pattern of serum E levels during gestation in mares was similar to that observed 
in our previous results obtained using RIA [98, 99], indicating that CLEIA system 
correctly monitored the physiological changes in circulating E during the gestation.  
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Pregnancy with placentation is a peculiarity of mammals, including horses. 
Remarkable fetal growth occurs in the uterus during the late stages of pregnancy 
in all mammals. The most important factor includes the rapid elongation and 
cylindrical changes in the uterus to maintain fetal survival at the stage of rapid 
fetal growth during the late stages of pregnancy [41, 94–96]. P, E, prolactin and 
relaxin play key roles in the implantation of embryos, maintenance of pregnancy, 
and induction of parturition. Although the synergistic action of P and E is generally 
essential for mares, as in most mammals, for maintaining successful pregnancy, E 
plays a dominant role in the maintenance of uterine elongation when the fetus 
grows rapidly in late pregnancy [41, 94–96]. Therefore, monitoring circulating E 
and P is useful for detecting clinical signs of abortion, stillbirth, and perinatal fetal 
death late pregnancy in mares [48, 61, 68, 83].  
E measurement is used to diagnose reproductive conditions at the equine 
clinic, and there is a need for a rapid measurement system in addition to the use 
of whole blood samples. In the present study, E concentrations in both whole blood 
and serum samples could be measured by CLEIA system within 30 min without 
ether extraction. Almost all the procedures were done automatically. This simple 
procedure makes hormonal evaluation by CLEIA system be an option for diagnosis 
of placental condition in pregnant mares in clinical practice. The only important 
point concerning the measurement of E by CLEIA system for use in the equine 
clinic is the detection limit of the assay. The basal level of circulating E during the 
estrous cycle [22, 58, 62, 63, 67] and the developmental stage [24, 49, 60, 66, 93] in 
mares is less than 20 pg/ml, and the detection limit of E by CLEIA system is 20 
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pg/ml. Extraction of E from serum by ether or other chemicals [64] will be required 
for measuring the basal E level in mares using this CLEIA system 
In conclusion, CLEIA system would be useful in the equine hospitals as an 
accurate diagnostic tool for the rapid assay of E in pregnant mares [102]. 
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Figure 1.2.1 Serum estradiol (E) concentrations of two pregnant mares, as 
measured by chemiluminescent enzyme immunoassay (CLEIA) (●) and 
fluoroimmunoassay (FIA) (○).  
E concentrations between last mating and 1 month after foaling were 
shown. “0” and “D” represent the days of copulation and delivery, respectively.  
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Figure 1.2.2 Correlation plots of estradiol (E) concentration in serum of pregnant 
mares measured by chemiluminescent enzyme immunoassay (CLEIA) and 
fluoroimmunoassay (FIA). 
E concentrations measured by two methods were strongly correlated (r = 
0.9521). 
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Figure 1.2.3 Correlation plots of estradiol (E) concentrations in the whole blood 
and serum of mares measured by chemiluminescent enzyme immunoassay.  
E concentrations in whole blood and serum were strongly correlated (r = 
0.9341).  
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Figure 1.2.4 Changes in circulating estradiol during pregnancy of mares measured 
by chemiluminescent enzyme immunoassay system.  
Results are expressed as means ± standard error of the mean (SEM) (n = 
9-22). Values less than 20 pg/ml are described as white circles.   
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Section 3. Testosterone 
1.3.1. Introduction 
Testosterone (T), an androgenic hormone, plays important roles in various 
aspects of male reproduction including sexual behavior [55], spermatogenesis [26, 
39] and construction of the blood-testis barrier [59]. Thus, T can be used as an 
indication of normal or abnormal reproductive function in males. Typically, T 
response to gonadotropin-releasing hormone (GnRH) or human chorionic 
gonadotropin (hCG) has been used for evaluation of fertility in many species 
including men [107], bulls [23], goat bucks [80], elephant bulls [86] and stallions 
[12, 72, 77, 78, 85]. While the GnRH challenge test enables evaluation of pituitary 
responsiveness in addition to testicular function by measuring luteinizing hormone 
(LH) or T concentrations, only testicular function can be assessed by the hCG 
challenge test. In clinical settings, the hCG challenge test seems a logical choice 
for evaluation of the testicular response of T secretion to the GnRH challenge test. 
The hCG challenge test can be performed in both breeding season and non-
breeding season [76]. In stallions, for example, the hCG challenge test may be used 
to determine whether a stallion has cryptorchid testes 
(cryptorchidism) or has been castrated when testes are not found in the scrotum[4, 
75]. 
Treatment with T products is also used in stallions with decreased libido 
[56]. When T products are used, monitoring of circulating T concentrations is 
strongly recommended to avoid overdosage of T products, which may result in 
testicular degeneration [10, 56].  
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In the present study, the usefulness of the CLEIA system for serum T assay 
in stallions was verified by comparing the results with T concentrations measured 
by a FIA, which has been used in stallions [49]. Then T measurement by the CLEIA 
system using whole blood as samples was verified for field use. Finally, the 
usefulness of the CLEIA system for evaluating testicular function in four typical 
cases found in the management of stallions was examined.  
 
1.3.2. Materials and Methods 
Animals 
12 (No. 1 to 12) of various breeds in Hokkaido, Japan that were aged from 
2 to 26 years were used in the present study (Tables 1.3.1, 1.3.2 and 1.3.3). They 
were kept in a pasture during the day and were housed individually in stalls at 
night or they were kept in individual stalls with a paddock. They were fed a 
maximum of 2 kg of concentrated feed per day with hay and water ad libitum. 
 
Sample Collection 
Blood samples were taken from the jugular vein into plain tubes for serum 
and into heparin sodium-loaded tubes for whole blood. The plain tubes were 
centrifuged at 1,700 xg for 10 min to separate serum, and serum samples were 
stored at -20oC until assay. The assay was performed on the same day as collection 
of whole blood. All procedures were carried out in accordance with the guidelines 
established by the institutional Animal Care and Use Committee of Tokyo 
University of Agriculture and Technology. 
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Hormone Assay 
1) CLEIA System 
Concentrations of T in serum and whole blood were measured by a CLEIA 
system using a reagent cartridge for the T assay (PF0191-K, LSI Medience 
Corporation) without extraction as described in section 1. The assay range of T by 
CLEIA was between 0.1 and 16.0 ng/ml. The intra-assay coefficients of variation 
were 8.9% at 0.87 ng/ml and 5.6% at 11.60 ng /ml for serum and they were 11.1% 
at 0.90 ng/ml and 4.2% at 14.60 ng/ml for whole blood according to the catalogue 
of the manufacturer.  
 
2) FIA 
Serum concentrations of T were measured by using a time-resolved FIA kit 
(DELFIA, PerkinElmer, Waltham, MA, U.S.A.) as described in section 2. The assay 
range of T by FIA was between 0.4 and 50.0 nmol/l (0.115 and 14.421 ng/ml). The 
intra- and inter-assay coefficients of variance were 6.0% and 12.9% at 1.20 ng/ml, 
5.5% and 6.8% at 2.94 ng/ml and 5.6% and 5.6% at 7.95 ng/ml, respectively, 
according to the catalogue of the manufacturer. 
 
3) RIA for luteinizing hormone (LH) concentrations 
Serum concentrations of LH were determined by using RIA system as 
described previously [21]. 100 µl of standard in PBS (0.05M) containing 5% of BSA 
and sample were prepared. 50 µl of antiserum against equine LH (cat. no. AFP-
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240580, provided by NIDDK. NIH, Bethesda, MD, U.S.A.) in PBS containing 
normal serum and EDTA (0.05M), and incubated at 4°C for 24 hr. After incubation, 
50 µl of secondary antibody, anti-rabbit gamma globulin for LH diluted with PBS 
(0.05M) containing 5% polyethylene glycol, was added and incubated at 4°C for 24 
hr and centrifuged at 1,700 ×g for 30 min at 4°C. After supernatant was removed 
and extra drops were swabbed, radioactivity was counted by gamma-counter. 
Highly purified equine LH (cat. no. AFP-5130B) was used for radioiodination and 
the reference standard. Intra-assay and inter-assay coefficients of variance were 
12.6% and 15.1%, respectively.  
 
Histological examination 
The testes of the stallion 12 were examined histopathologically after 
orchiectomy in December 2014 (16 years of age). Orchiectomy was performed under 
general anesthesia that was induced with detomidine hydrochloride (Virbac, 
Milperra, Australia), diazepam (Takeda Pharmaceutical Company Limited, Osaka, 
Japan) and ketamine (Daiichi Sankyo Propharma, Tokyo, Japan) and maintained 
with isoflurane (Intervet, Tokyo, Japan).  
A part of the testicular parenchyma was taken from the center of each 
testes. Samples of the testes were fixed in 10% buffered formalin, dehydrated, and 
embedded in paraffin. The paraffin-embedded testes were serially sectioned at 4 
µm in thickness, and serial sections were treated with xylene and graded ethanol 
and then stained with hematoxylin and eosin and Masson trichrome stain. Testes 
of an adult Thoroughbred stallion that died at the age of 21 year due to 
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arteriorrhexis were used for a control. 
For immunohistochemical (IHC) examination, testicular tissues were 
immune-stained against the equine LH receptor. Testicular paraffin sections were 
rinsed with 0.05% Triton-X 100 in phosphate buffered saline (PBS), and non-
specific binding sites were blocked using 10% normal goat serum and 0.05% Tween 
20 in PBS before incubation with a primary antibody. Epitope retrieval was carried 
out using a microwave (15 min in antigen retrieval citrate buffer, 10 mM sodium 
citrate, pH 6.0). After cooling down to room temperature, the sections were 
incubated overnight at 4°C with an anti-equine LH receptor antibody (rabbit 
polyclonal antibody, 1:20 dilution, Biorbyt, Cambridge, UK). The sections were 
rinsed in distilled water, followed by treatment with a biotinylated goat anti-rabbit 
IgG (Vector Laboratories, Burlingame, CA, U.S.A.) by the ABC method with a 
commercially available kit (Vector Laboratories). Immunostaining using a primary 
antibody was visualized using 3, 3’-diaminobenzidine tetrahydrochloride as a 
substrate (Sigma-Aldrich, St Louis, MO, U.S.A.) and counterstaining with 
hematoxylin.  
 
Experimental Design 
Study 1 
To determine whether the CLEIA system can be used for stallion serum, 
serum T concentrations measured by the CLEIA system were compared with those 
measured by FIA. To create a broad range of circulating T concentrations, stallions 
1 to 4 without any clinical signs were administered a single dose of 10,000 IU of 
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hCG (GESTORON 5000, Kyoritsu Seiyaku Corporation, Tokyo, Japan) 
intramuscularly (Table 1.3.1). Blood samples were taken immediately before and 
hourly until 6 hr after hCG administration and then daily for 7 days (n=56). Serum 
T concentrations were measured by the CLEIA system and FIA. 
 
Study 2 
To validate direct use of whole blood samples for the CLEIA system, T 
concentrations in whole blood and serum were determined with the CLEIA system. 
The system accommodates T concentrations in whole blood using hematocrit levels. 
In this study, the hematocrit level was fixed to 40%. Stallions 5 to 8 were 
administered T enanthate (Enarmon Depot, ASKA Pharmacoutical Co., Ltd, Tokyo, 
Japan) intramuscularly. Doses and protocols of administration and also blood 
sampling schedules are shown in Table 1.3.2 (n = 64). Stallions 7 and 8 were used 
twice with different protocols at an interval of 47 days.  
 
Study 3    
To evaluate the practical value of the CLEIA system, four stallions (Stallion 
9 to 12) with reproductive abnormalities (Table 1.3.3) were subjected to hCG 
challenge tests.  
Both testes of stallion 9 were smaller than normal size reported previously 
[100] when the stallion was introduced to the stud after retiring from racing. 
Stallion 10 had bilaterally enlarged testes compared with normal testicular size 
[100] and the testes were suspected to be tumors. Stallion 11 had no palpable testes 
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in the scrotum and no record of castration when the animal was introduced to our 
stud. When a mare at estrus came close, stallion 11 mounted and ejaculated as 
judged by the observation of tail flagging, but no spermatozoa was observed in the 
dismount semen. Stallion 12 had been used for mating and proven fertile in 2013. 
In 2014, at the age of 16, the number of sperm in the dismount semen was few and 
testicular atrophy was observed. Testicular size in stallion 12 was shown in Table 
1.3.3. Stallion 9 was administered 5,000 IU of hCG intravenously [12] and stallions 
10, 11 and 12 were administered 10,000 IU of hCG [85]. After administration of 
hCG, serum samples were obtained as in Study 1. Serum T concentrations were 
measured by the CLEIA system. In stallion 11, hCG challenge tests were 
performed twice at an interval of two months. Stallion 12 was subjected to hCG 
challenge test in 2010 for hCG trial in fertile stallions and T concentrations were 
measured by RIA. To evaluate the endocrine function of the hypothalamus-
pituitary-gonadal axis, basal concentrations of LH and T in stored serum were 
measured in stallion 12 during the breeding and non-breeding seasons in 2014 (16 
years of age) and in 2009 to 2013 (11-15 years of age). Blood samples were collected 
from the jugular vein of stallion 12 during the breeding season (n = 4, April to July 
in 2014) and during the non-breeding season (n = 3, September to November in 
2014). Blood samples were also collected from stallion 12 before the development 
of testicular atrophy in the breeding season (n = 5, April, 2009 to 2013) and in the 
non-breeding season (n = 5, October, 2009 to 2013). Blood samples were also 
collected from apparently normal Thoroughbred stallions from 14 to 16 years of 
age during the breeding season (n = 6, April) and the non-breeding season (n = 6, 
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October) as controls. Serum concentrations of LH were determined by RIA and 
serum concentrations of T were measured by a CLEIA system.  
 
Statistics 
In Studies 1 and 2, Pearson’s correlation (r) was calculated as described in 
section 1. In Study 1, Dunnett’s multiple comparison test was performed for 
comparison of T concentrations after administration of hCG with those before 
administration by using GraphPad Prism 5 for Windows. In study 3, One-way 
ANOVA and Tukey’s multiple comparison test were performed to detect significant 
changes in the concentrations of LH and T of stallion 12 using GraphPad Prism 
version 5.  
 
 
 
1.3.3. Results 
Study 1 
Serum T concentrations measured by the CLEIA system and FIA showed 
a strong correlation (r = 0.9865, P < 0.01, n = 56, Fig. 1.3.1). Changes in serum T 
concentrations after hCG administration measured by the CLEIA system and FIA 
were similar (Fig. 1.3.2). Serum T concentrations showed bimodal peak. The first 
peak appeared within 3 hr after administration of hCG, and the second one 
appeared 3 or 4 days after administration of hCG. T concentrations between 2 and 
5 days after administration of hCG were significantly higher than those before 
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administration.   
 
Study 2 
Whole blood T concentrations and serum T concentrations measured by the 
CLEIA system showed a strong correlation (r = 0.9665, P < 0.01, n = 64, Fig. 1.3.3). 
Changes in T concentrations in whole blood after T product administration in each 
stallion are shown in Fig. 1.3.4. T concentrations increased after single 
administration of 100 mg or 250 mg or double administrations of 100 mg T 
enanthate; however, the increase was not clear. T concentrations after double or 
quarterly administrations of 250 mg T enanthate clearly increased.  
 
Study 3 
In stallion 9, serum T concentrations showed bimodal changes similar to 
those in normal stallions 1 to 4 (Figs. 1.3.2 and 1.3.5a). Stallion 10 showed no 
obvious increase in serum T concentration during the seven-day study period after 
hCG administration (Fig. 1.3.5b). In stallion 11, serum T concentration showed no 
increase for the first 6 hr but increased after 24 hr. Serum T concentrations after 
the second administration tended to be lower than those after the first 
administration (Fig. 1.3.5c). Stallion 12 had subjected to hCG challenge test four 
years before the present study (12 years of age) and had shown an increase in T 
indicating a normal testicular function. However, an increase in the serum 
concentration of T was not observed after intravenous administration of hCG in 
the present study (Fig. 1.3.5d). In breeding season, serum concentrations of LH of 
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stallion 12 in 2014 (16 years of age), after testicular atrophy had developed, were 
significantly higher than those in 2009 to 2013 (11-15 years of age), before 
testicular atrophy had developed and controls. In non-breeding season, serum 
concentrations of LH of stallion 12 in 2014 were also significantly higher than 
those of stallion 12 from 2009 to 2013 and controls (Fig. 1.3.6a). Although serum 
concentrations of T in breeding season tended to be higher than those in non-
breeding season, there was no significant difference among the groups (Fig. 1.3.6b). 
The stallion was retired from mating and castrated. The testes were examined 
histologically. It was revealed that there were seminal tubules with arrested 
spermatogenesis and sertoli cells within these seminal tubules had large empty 
intracytoplasmic vacuoles (Fig. 1.3.7b, d). The amount of collagen fibers was 
increased (Fig. 1.3.7f). Leydig cells in the testes were swollen (Fig. 1.3.7d) and LH 
receptors were not detected by IHC in Leydig cells in the testes of stallion 12 (Fig. 
1.3.7h). 
 
1.3.4. Discussion 
The present study demonstrated that the CLEIA system can be used for 
measurements of T concentrations in stallions. First, serum T concentrations 
measured by the CLEIA system were compared with those measured by FIA, an 
established assay system for stallion serum T measurement [49]. T concentrations 
measured by the CLEIA system were almost the same as those measured by FIA 
(r = 0.9867). Furthermore, the secretion pattern of T was very similar to that 
reported previously [12]. These results together with the rapidity of the CLEIA 
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system indicated that the system is a valuable and practical system for measuring 
T concentrations in stallions as an alternative to FIA. T concentrations can be 
measured in a much shorter time by the CLEIA system than by FIA (30 min vs 3 
hr). Furthermore, the CLEIA system allows us to obtain results with a single step 
of sample application on a reagent cartridge, while the FIA system requires 
complex and multiple manipulations.   
T concentrations in whole blood measured by the CLEIA system were 
almost the same as those in serum (r = 0.9665). This system accommodates T 
concentrations in whole blood by using hematocrit levels. In a previous study 
conducted in human subjects, T concentrations in whole blood were found to be 
strongly correlated with those in serum when hematocrit levels were fixed at 40% 
[18]. In the present study, hematocrit levels were also fixed at 40% according to 
that previous study, and T concentrations in whole blood were found to be highly 
correlated with those in serum in stallions. The rapidity and compatibility of whole 
blood as samples for the CLEIA system may make the system a useful tool and 
enable better T therapy for decreased libido. It is difficult to determine the dose 
and timing of T administration to achieve effective blood T levels and to avoid 
overdosing. In this study, a single administration of 100 or 250 mg and double 
administrations of 100 mg of T enanthate did not result in high T concentrations 
in circulation. Administration of 250 mg T enanthate for more than 2 days resulted 
in an increase in T concentrations for several days. Administration of T enanthate 
is used for stallions with decreased libido; however, it has been shown that 
administration of an excess amount of T impaired spermatogenesis and decreased 
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the testicular volume in stallions [10]. Administration of T enanthate is an option 
for treatment of low libido in my experience. Previously, one stallion in my stud 
with low libido was able to mount with an increase of T concentrations by 
administration of T enathate. However, blood T levels to be attained for restoring 
libido are unknown, and an appropriate T administration protocol has not been 
established [56]. Obviously, further research is needed, and the CLEIA system used 
in the present study would be a useful tool.  
Measurement of T concentrations is often needed in a stud. The risk of 
reproductive abnormalities, such as testicular degeneration and testicular tumor, 
increases with aging [87, 106]. When stallions are moved from one farm to another, 
their clinical records sometimes become uncertain. If a stallion shows an absence 
of testes in the scrotum, it must be determined whether the stallion was castrated 
or whether the stallion has cryptorchid testes. In a Thoroughbred stud, some 
stallions would have been retired from racing at the end of the year, and the period 
between retirement from racing and the start of breeding would be only 2 to 3 
months. Stallions are trained to mate with mares during this short period. Some 
stallions may take a while to start mounting mares and may have low libido. 
Although the frequency may be low, some new young stallions retiring from racing 
have small testes compared with testes in stallions of equivalent age. In such cases, 
veterinarians in the stud must evaluate the testicular function of these stallions. 
Measurement of T concentration with or without hCG challenge may be useful for 
distinguishing cases of cryptorchidism and castration, and hCG challenge is also a 
useful method for distinguishing infertile and normal stallions. In this study, four 
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stallions with suspected reproductive abnormalities were subjected to the hCG 
challenge test, and the response of T concentrations was determined by using the 
CLEIA system.  
Stallion 9 with small testes showed a T response to hCG that was similar 
to the response found in normal stallions in Study 1 (Fig. 1.3.2). The observed T 
response suggested normal reproductive ability of stallion 9. The conception rate 
of stallion 9 in the first breeding season was more than 70%, indicating that the 
testes of stallion 9 were small because of individual difference and that 
spermatogenesis in stallion 9 was normal.  
In stallion 10 with enlarged testes, T concentrations did not increase after 
hCG administration, indicating the possibility that Leydig cells had lost their 
steroidogenic capacity. The stallion died one year and four months after the hCG 
challenge test. The testes were examined histologically and a diagnosis of 
seminoma was made. Seminoma generally does not affect T production [30]. 
Testicular sizes when stallion 10 died were larger (left: 24.0 x 17.0 x 11.0 cm, right: 
26.0 x 14.5 x 9.0 cm) than the sizes when the hCG challenge test was performed. 
It is no clear whether seminoma influenced the ability of T secretion.     
In stallion 11, an increase in T concentrations after hCG administrations 
indicated the presence of testes [4, 75]; thus, stallion 11 was diagnosed as having 
cryptorchid testes, not having been castrated. Stallion 11 was castrated by using 
laparoscopy to prevent cryptorchidism from developing into tumors [50, 88]. Both 
testes were found in the abdominal cavity. T concentrations after the second 
administration tended to be lower than those after the first administration. It is 
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unlikely that antibodies against hCG were produced after a single administration 
of hCG [79]. It was not clear why T concentrations after the second experiment 
were lower than those after the first experiment in this study.  
In stallion 12 in 2010 (12 years of age), following administration of hCG, 
serum concentrations of T increased and reached the first peak at 4 hr, and 
declined gradually. The serum concentrations of T began to increase again from 
the second day and reached the second peak 3 days after hCG administration, 
followed by a gradual decline by 7th days after hCG administration. On the other 
hand, an increase in the serum concentrations of T was not observed after 
intravenous administration of hCG in stallion 12 in this study in 2014 after 
development of testicular atrophy (Fig. 1.3.5d), indicating that Leydig cells in the 
testes of stallion 12 lost reactivity to hCG due to loss of LH receptors in Leydig 
cells. Our previous studies demonstrated that there were clear seasonal changes 
in circulating LH and T in Thoroughbred stallions [25, 65]. The highest and lowest 
circulating concentrations of both LH and T were observed in the breeding and 
non-breeding seasons, respectively. Basal T concentrations in stallion 12 in 2014 
were not different from T concentrations in stallion 12 before 2013 and controls. In 
the meantime, LH concentrations in stallion 12 in 2014 were significantly higher 
than those in stallion 12 before 2013 and controls. Although LH concentrations 
were affected by season, LH concentrations of stallion 12 in non-breeding season 
in 2014 remained high compared with those in other groups. This result was 
consistent with the loss of LH receptors in Leydig cells [104].    
In these clinical cases, T measurement by the CLEIA system was useful for 
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evaluation of testicular function and for judging the existence of normal testicular 
tissue.  
The minimum detection level of the CLEIA system for human is 0.1 ng/ml. 
It may not be sensitive enough to measure basal T concentration at rest in a 
stallion which is as low as 300 and 402 pg/ml in the non-breeding and breeding 
seasons, respectively [42]. Therefore, a sample may need to be concentrated to ten 
times, for example, to determine the actual blood concentration, although that may 
jeopardize the rapidity and simplicity of the system. 
In conclusion, it was shown that the CLEIA system can be used for 
measuring T concentrations in both serum and whole blood of stallions. By using 
the CLEIA system, it is possible to measure T concentrations rapidly and easily. 
The system is useful for diagnosis of reproductive abnormalites by an hCG or 
GnRH challenge test and for treatment of stallions with low libido by 
administration of a T product in the Thoroughbred industry [103].  
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Table 1.3.1 Breed, age, clinical signs, and hCG challenge protocol of stallions in 
Study 1. 
 
 
 
 
 
 
 
 
 
 
 
Stallion 
No. Breed Age 
hCG Dosage 
(IU) Clinical findings Date 
1 Warmblood 2 10,000 No clinical symptom 2010/9/23
2 Warmblood 2 10,000 No clinical symptom 2010/9/23
3 Warmblood 2 10,000 No clinical symptom 2010/10/4
4 Halfbred 3 10,000 No clinical symptom 2010/10/7
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Table 1.3.2 Breed, age, and T administrations protocol of stallions in Study 2.  
a The second T enanthate treatment for both stallions 7 and 8 were started 47 days 
after the first day of the first treatment.  
 
 
 
 
 
 
 
 
 
 
Stallion 
No. 
Breed Age 
Dosage  
per 
treatment 
(mg) 
No. of days 
for daily 
treatments
Period of 
daily blood 
collection 
Date of T 
administration
5 Halfbred 7 100 1 Day 0 to 7 2013/1/7 
6 Warmblood 4 100 2 Day 0 to 7 2013/1/7 
7(1st) Warmblood 4 250 1 Day 0 to 8 2013/1/7 
7(2nda) 250 4 Day 0 to 14 2013/2/23 
8(1st) Halfbred 6 250 2 Day 0 to 8 2013/1/7 
8(2nda) 250 4 Day 0 to 14  2013/2/23 
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Table 1.3.3 Breed, age, clinical signs and hCG challenge protocol for stallions in 
Study 3. 
 
a Testicular sizes are indicated as length x height x width (cm). 
b Stallion 11 was administered 10,000 IU of hCG twice with an interval of two 
months. 
c Stallion 12 was performed hCG challenge test in 2010, before development of 
testicular atrophy. At that time, T concentrations were measured by RIA.  
 
 
 
Stallion 
No. Breed Age 
hCG Dosage 
(IU) Clinical findings Date 
9 Thoroughbred 9 5,000 Small size testes, 
left: 6.4 x 2.9 x 2.7, 
right: 7.6 x 4.1 x 2.7a 
2011/1/8 
10 Haflinger 26 10,000 Enlarged testes suspected 
tumor, 
left: 19.4 x 13.0 x 10.2, 
right: 20.8 x 14.0 x 12.0a 
2013/1/29
11b Warmblood 3 10,000 Absence of testes in the 
scrotal, suspected 
cryptorchidism or 
castrated 
2015/9/4, 
2015/11/17
12c Thoroughbred 16 10,000 Testicular atrophy, 
left: 6.7 x 3.4 x 4.5, 
right: 6.2 x 3.7 x 2.5a 
2014/2/16
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Fig. 1.3.1 Correlation of testosterone (T) concentrations in serum measured by the 
chemiluminescent enzyme immunoassay (CLEIA) system and by 
fluoroimmunoassay (FIA).  
Stallions 1 to 4 were administered 10,000 IU of human chorionic 
gonadotrophin (hCG) intramuscularly, and T concentrations in blood samples (n = 
56) were measured by the CLEIA system and FIA. T concentrations measured by 
the two methods were strongly correlated (r = 0.9865).  
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Fig. 1.3.2 Comparison of testosterone (T) concentrations measured by the 
chemiluminescent enzyme immunoassay (CLEIA) system and by 
fluoroimmunoassay (FIA).  
 Four stallions (1 to 4) with no clinical signs were administered 10,000 IU 
of human chorionic gonadotrophin (hCG). T concentrations in serum samples were 
measured by the CLEIA system and FIA. T concentrations are shown as averages 
± SEM. The left vertical axis shows hourly data and the right vertical axis shows 
daily data. An asterisk indicates that the mean of T concentrations is significantly 
higher than that before administration. 
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Fig. 1.3.3 Correlation of testosterone (T) concentrations in whole blood and serum 
measured by the chemiluminescent enzyme immunoassay (CLEIA) system.  
Stallions 5 to 8 were administered (i. m.) T enanthate (100 or 250 mg) for 
1 to 4 days (daily). Blood samples (n = 64 in total) were collected before and after 
T enanthate administration for 5 to 8 consecutive days. See Table 1.3.2 for details 
of the T enanthate treatment protocol in each stallion. 
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Fig. 1.3.4 Concentrations of testosterone (T) in whole blood after T enathate 
administration.  
Stallions 5 to 8 were administered T enathate as shown in Table 1.3.2. 
Arrows indicate administration of T enathate.  
 
 
 
53 
 
 
0
1
2
3
4
5 (b) Stallion 10: Seminoma
Hours                   Days
After hCG administration
0 3 6 1 2 3 4 5 6 7
Te
st
os
te
ro
ne
 (n
g/
m
l)
0
1
2
3
4
5 (a) Stallion 9: Small testes
0 3 6 1 2 3 4 5 6 7
Te
st
os
te
ro
ne
 (n
g/
m
l)
0
1
2
3
4
5
1st
2nd
(c) Stallion 11: Cryptorchid testes
0 3 6 1 2 3 4 5 6 7
Te
st
os
te
ro
ne
 (
ng
/m
l)
0
2
4
6
8
10
0 1 2 3 4 5 6 73 6
(d) Stallion 12: Testicular atrophy
; 2010
; 2014
Hours Days
After hCG administration
Te
st
os
te
ro
ne
 (n
g/
m
l)
 
Fig. 1.3.5 Changes in serum testosterone (T) concentrations after human chorionic 
gonadotropin (hCG) administration in stallions with reproductive abnormalities.  
Stallion 9 (5,000 IU) and stallions 10, 11 and 12 (10,000 IU) were 
administered hCG to determine T responses to hCG administration. See Table 
1.3.3 for clinical findings of each animal. Stallion 11 was administered hCG twice 
with a two-month interval. Stallion 12 was performed hCG challenge test in 2010. 
T concentrations were measured by radioimmunoassay at that time.  
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Figure 1.3.6 Basal concentrations of circulating luteinizing hormone (LH) (a) and 
testosterone (b) in a Thoroughbred stallion (stallion 12) during the breeding (April 
to July) and non-breeding seasons (September to November) and in the intact adult 
Thoroughbred stallion.  
  Stallion 12 in 2014 after the development of testicular atrophy in the 
breeding season (n = 4). Stallion 12 in 2014 after development of testicular atrophy 
in the non-breeding season (n = 3). Stallion 12 in 2009-2013 before the development 
of testicular atrophy in the breeding season (n = 5). Stallion 12 in 2009-2013 before 
the development of testicular atrophy in the non-breeding season (n = 5). Intact 
Thoroughbred stallions in the breeding season (n = 6). Intact Thoroughbred 
stallions in the non-breeding season (n = 6). Results are expressed as means ± SEM. 
x, y or X, Y: means are significantly different within the same season (P < 0.05). 
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Figure 1.3.7 Histological (a-f) and immunohistochemical (g, h) observations of the 
testes of an intact Thoroughbred stallion (a, c, e, g) and Thoroughbred stallion 12 
(b, d, f, h).  
 Complete spermatogenesis was observed within the lumen of the intact 
adult Thoroughbred stallion (a, c). Spermatogenesis was arrested in stallion 12 (b, 
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d). Sertoli cells within tubules had large empty intracytoplasmic vacuoles in 
stallion 12 (d, +). Leydig cells (d, white arrowhead) were swollen. The amount of 
collagen fibers was increased (f, #). In immunohistochemical sections, LH receptors 
were observed in Leydig cells in the testes of an intact adult Thoroughbred stallion 
(g, black arrow) but not in Leydig cells in the testes of stallion 12 (h). a-d: 
Hematoxylin and eosin stain. e, f: Masson trichrome stain. g, h: immune-stain 
against the equine LH receptor. Bars in panels a, b, e and f represent 200 µm, bars 
in panels c and d represent 40 µm, and bars in panels g and h represent 10 µm.  
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Summary 
In order to evaluate the validity of chemiluminescent enzyme 
immunoassay (CLEIA) system for measurement of progesterone (P), estradiol (E) 
and testosterone (T) concentrations in horses, concentrations of P, E and T 
measured by CLEIA system were compared with those measured by 
radioimmunoassay (RIA), enzyme immunoassay (EIA) or fluoroimmunoassay 
(FIA). CLEIA system showed significant correlations with those assays and it is 
confirmed that CLEIA system can be used for evaluation the concentrations of P, 
E and T in horses. CLEIA system for measurement of P concentrations in mares 
are useful for evaluation of corpus luteum. It is helpful to distinguish mares in 
diestrus from those in estrus at the mating in stud. CLEIA system for 
measurement of E concentrations in pregnant mares are useful for evaluation the 
placental function. However, it cannot use for non-pregnant mares because E 
concentrations in non-pregnant mares are lower than the assay limit of CLEIA 
system, 20 pg/ml. CLEIA system for measurement of T concentrations in stallions 
is useful for evaluation of testicular function after human chorionic gonadotrophin 
(hCG) challenge test, diagnosis for cryptorchidism and monitoring the fluctuation 
of T concentrations after T product administration.  
Hormonal concentrations of P, E and T in whole blood samples measured 
by CLEIA system and compared with those measured in serum samples by CLEIA 
system. Concentrations of P, E and T in whole blood showed a strong correlation 
with those in serum samples. Whole blood samples can be used as serum samples 
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for measurement by CLEIA system. It becomes possible to get result of hormonal 
concentrations rapidly by using whole blood samples measured by CLEIA system.  
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CHAPTER II Management of equine coital exanthema presenting serious 
problems in stud 
 
 
 
 
 
 
 
 
 
 
 
Section 1. Clinical cases of equine coital exanthema and trial of treatment with 
valacyclovir 
 
2.1.1. Introduction 
Equine coital exanthema (ECE) is caused by equine herpesvirus 3 (EHV-3), 
which is a member of the Varicellovirus genus, subfamily Alphaherpesvirinae. 
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EHV-3 causes latent infection as do other herpesvirus [7–9]. The prevalence of the 
virus in Japan is unknown. Equine herpesvirus 1 and 4 are also members of the 
Varicellovirus genus, subfamily Alphaherpesvirinae. These are cause of equine 
rhinopneumonitis and abortion. Equine rhinopneumonitis is a notifiable-infectious 
disease, but ECE is not. EHV-3 is transmitted via both direct contact and indirect 
contact. It is also transmitted by coitus and artificial insemination [2, 6, 9, 29]. 
Infection with the virus results in the development of papules, vesicles, pustules 
and ulcers on the vaginal area in mares and on the penis and prepuce in stallions 
[2]. These regional symptoms are cured in two to three weeks [2, 7, 29, 35, 81]. 
Treatments for the disease are very limited. In Japan, firing the affected area with 
silver nitrate has been used on a regular basis. An antibiotic is used for prevention 
of complications [29, 81]. Some researchers have investigated the effectiveness of 
acyclovir, an anti-herpesvirus agent [2, 6, 19, 81]; however, the effectiveness of 
valacyclovir, a prodrug of acyclovir, has not been reported. 
The occurrence of ECE has been reported in many countries [6, 47, 81]. In 
Japan, symptoms suggesting ECE have been reported, but isolation of EHV-3 was 
reported in only one case. It was isolated from draft mares in Iwate Prefecture in 
2004 [81].  
As reported here, two stallions developed symptoms suggestive of ECE, and 
EHV-3 was isolated from both stallions. Valacyclovir and acyclovir, anti-
herpesvirus agents, were used for treatment, and it was investigated whether 
valacyclovir is effective for treating ECE. 
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2.1.2. Materials and Methods 
Cell culture and virus 
Fetal horse kidney (FHK) cells were cultured in Eagle’s minimum essential 
medium (MEM) supplemented with 10% fetal calf serum (FCS) and used for virus 
isolation and serum neutralization (SN) tests. For the maintenance medium, the 
serum concentration was reduced to 4%. The Iwate-1 strain was propagated in 
FHK cells and used as the reference strain of EHV-3 in this study [81].  
 
Samples from affected horses 
Stallion A and stallion B developed ECE clinically on April 10, 2015 and 
May 14, 2015, respectively. The day after the onset, swabs were obtained from 
penile lesions of both stallions and placed in 1 ml of MEM supplemented with 50 
µg/ml of gentamycin. The eluted samples were centrifuged at 670 ×g for 10 min at 
4°C to pellet debris, and the supernatant fluids were used for virus isolation.  
 
Virus isolation 
100 µl of each of the supernatant fluids of swab samples was inoculated 
onto FHK cells cultured in a 6-well plate (Thermo Fisher Scientific, Waltham, MA, 
U.S.A.). After adsorption at 37°C for 30 min under a 5% CO2 atmosphere, the cells 
were washed twice with MEM and the maintenance medium was added. Then the 
cells were cultured at 37°C under a 5% CO2 atmosphere.  
 
Serum samples 
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Sera from stallions A and B were collected on April 11, April 27, May 27, 
June 30, July 27 and August 31 in 2015, and on May 15, June 3 and September 16 
in 2015, respectively.  
 
SN test 
Antibodies against EHV-3 in sera were determined by the SN test using 
the EHV-3 isolate from the stallion A and FHK cells as described previously [81]. 
Serial two fold dilutions, beginning with a 1:2 dilution, of the serum were mixed 
with an equal amount of the EHV-3 isolate containing a 200 median tissue culture 
infectious dose per 0.1 ml before incubation at 37°C for 60 min. One well of cell 
cultures was inoculated with 0.1 ml of each virus-sample mixture and incubated 
at 37°C. The results were read 7 days postinoculation. SN titer was expressed as 
the reciprocal of the highest dilution that completely inhibited CPE.     
 
Plaque reduction assays 
Antiviral activity of valacyclovir (Sigma-Aldrich, St. Louis, MO, U.S.A.) 
and that of acyclovir (Sigma-Aldrich) against EHV-3 were determined. FHK cells 
were seeded in 6-well culture plates and were cultured in a growth medium (MEM 
supplemented with 10% FCS) at 37 °C for 24 hr. Then the growth medium was 
removed and FHK cell monolayers were cultured with various concentrations of 
each compound, from 1 mg/ml to 250 ng/ml in MEM supplemented with 4% FCS 
at 37°C for 24 hr. The culture medium was removed again and FHK cells were 
infected with 50 to 100 plaque-forming units of EHV-3/well. After 1-hr adsorption, 
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HFK cells were washed three times with MEM and overlaid with MEM containing 
the same concentration of each compound, 4% FCS and 0.9% Agar Noble (Difco, 
Detroit, MI, U.S.A). Plaques were counted two days after infection. The 50% 
effective concentration (EC50) for reduction in plaque number was calculated from 
dose-response curves generated from the data. 
 
2.1.3. Results 
Case 1 
Stallion A was a 14-year-old Thoroughbred. The stallion mated with two or 
three mares every day from mid of February until the occurrence of ECE. On April 
10, 2015, some papules were found on the penis, but this stallion mated with three 
mares on the same day (date of occurrence). The next day, the papules were 
ruptured and exudative fluid was observed. The stallion showed signs of pain by 
palpation of the penis, and mating was impossible. After EHV-3 was isolated from 
a penile swab [46], oral administration of valacyclovir (Valtrex, GlaxoSmithKline 
K. K., Tokyo), which is a prodrug of acyclovir and an anti-herpesvirus agent, was 
started (27 mg/kg/8 hr for 2 days, 18 mg/kg/12 hr for 8 days) [53] from the 2nd day 
of occurrence. Washing the affected area with hypochlorous acid solution (50 ppm, 
pH 6.5) and application of 1% nadifloxacin ointment were started on the same day. 
On the 3rd day, body temperature rose and appetite was lost. Flunixin meglumine 
was therefore administered (1.1 mg/kg). The affected area did not expand after 
starting administration of valacyclovir and gradually dried from the 5th day. Local 
treatment for the penis was stopped on the 8th day, and oral administration of 
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valacyclovir was stopped on the 11th day. Symptoms of the penile area are shown 
in Fig. 2.1.1a. The stallion started mating again on the 18th day, and the stallion 
had no problems with mating. The serum antibody titers are shown in Table 2.1.1. 
One of the three mares the stallion mated with on the date of occurrence developed 
papules 5 days after mating, and EHV-3 was isolated from a vaginal swab. 
 
Case 2 
Stallion B was a 13-year-old Thoroughbred. The stallion mated with one or 
two mares almost every day. On May 14, 2015, some papules had developed on the 
stallion’s penis and the number of papules gradually increased (date of occurrence). 
Some of the papules ruptured and exudate was observed. Because the symptoms 
were similar with those observed in stallion A, the stallion was administered 
valacyclovir orally at the same dose as that for stallion A on the date of occurrence 
before the isolation of EHV-3. In the results, EHV-3 was isolated from a penile 
swab [46]. For local treatment, the penis was washed with hypochlorous acid 
solution and 5% acyclovir ointment, an anti-herpesvirus agent, was applied from 
the 2nd day. The affected area did not expand from the 2nd day and the ruptured 
pustules gradually became scarred. Local treatment was stopped on the 7th day 
and oral administration of valacyclovir was stopped on the 10th day. Symptoms of 
the penile area in stallion B are shown Fig. 2.1.1b. The stallion started mating on 
the 19th day, and the stallion had no problems with mating. The serum antibody 
titers are shown in table 2.1.1. 
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Antiviral activity of valacyclovir 
The dose-response curves are shown in Fig. 2.1.2. The EC50 values are 3 
µg/ml for valacyclovir and 2.3 µg/ml for acyclovir. Both valacyclovir and acyclovir 
were effective for inhibiting replication of EHV-3. 
 
2.1.4. Discussion 
Symptoms suggestive for ECE have often been observed in Japan, but the 
exact causes were not investigated in most cases. Isolation of EHV-3 was reported 
previously in only one case in Japan and it was isolated from mares [81]. This is 
the first report of isolation of EHV-3 from stallions in Japan. The two stallions from 
which EHV-3 was isolated were kept at different studs. The distance between the 
two studs is more than 70 km, and the stallion handlers did not pass between the 
two studs in the breeding season. There was no mare that was mated in both of 
the stallions. Thus, it is possible that EHV-3 was prevalent subclinically among 
Thoroughbreds in Japan. 
During the occurrence of ECE, the stallions had to stop mating because 
there was pain by palpation of the penis and because EHV-3 is transmitted by 
coitus. Both of the stallions stopped mating for more than two weeks. Because their 
fees for mating were very high, financial losses were enormous and owners who 
planned to mate their mares with stallion A or B had to change their mating plan. 
ECE therefore has huge negative effects on the Thoroughbred racing horse 
industry.  
Stallions are at high risk for exposure to EHV-3 in the breeding season 
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because they are in contact with many mares, and popular stallions are very busy 
and under a lot of stress in the breeding season [6]. According to some reports, 
stress causes re-activation of the virus latently in infected horses [2, 9, 51]. 
Approaches to therapy for ECE are very limited. In Japan, firing the 
affected area with silver nitrate has been used, but this is painful and its effect is 
unknown. Some researchers have used acyclovir for treatment of ECE. In a 
previous study, a stallion and some mares with ECE responded well to application 
of acyclovir, and an inhibitory effect of acyclovir on EHV-3 was shown by plaque 
reduction assays [19]. Some researchers have used valacyclovir, a prodrug of 
acyclovir, for treatment of EHV-1 infection but not for treatment of EHV-3 infection 
[31–33, 53]. Some studies showed that valacyclovir maintained an effective serum 
concentration for a longer time than did acyclovir [31, 33, 53]. We therefore 
expected that valacyclovir would be more effective than acyclovir for treatment of 
ECE. We used valacyclovir for systemic treatment, and this is the first study in 
which valacyclovir was used orally for treatment of ECE. However, it took more 
than 2 weeks for both stallions to start mating again, and this period is almost the 
same as that when ECE was treated without an anti-herpesvirus agent [2, 7, 29, 
35, 81]. These results suggest that once papules have ruptured, it takes more than 
2 weeks for regeneration of the penile area. Treatment with valacyclovir did not 
greatly shorten the duration of disease. Garré et al. [32], reported that unbound 
plasma acyclovir concentrations were maintained between 1.7 µg/ml and 3.0 µg /ml 
after valacyclovir administration (40 mg/kg body, 3 times daily) in ponies. The 
isolate used in this study is susceptible to valacyclovir in vitro at a concentration 
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of 3.0 µg/ml. Therefore, in this study, the dosage regimen consisting of 27 mg/kg/8 
hr for 2 days and 18 mg/kg/12 hr for 8 days might have resulted in a plasma 
concentration that did not exceed the EC50 value of EHV-3. However, the affected 
area did not expand after oral administration of valacyclovir, suggesting the 
potential of valacyclovir for suppression of EHV-3 activity clinically. 
Stallion A was not a subclinical case and EHV-3 was transmitted from 
other mares because the stallion’s antibody titer had never increased for 8 years 
before occurrence. On the other hand, the antibody titer of stallion B before 
occurrence was not investigated, and whether the cause of ECE symptoms was re-
activation or transmission from mares was unknown. Serum antibody titers did 
not increase immediately after occurrence in contrast to the immediate increase in 
antibody titers in previous studies [7, 81], but they increased 2 months and 4 
months after occurrences in stallion A and stallion B. Oral administration of 
valacyclovir might suppress the increase in antibody titers. 
It has been reported that EHV-3 was transmitted not only from horses with 
symptoms but also from latently infected horses[2, 6, 9, 29]. Before mating, we 
checked the vaginal area of all mares, but symptoms of ECE were not found. The 
vaginal area was washed as in previous studies [2, 6]. In those previous studies, 
washing the vaginal area reduced the risk of transmission. In these cases, the 
vaginal area was washed with hypochlorous acid solution. Virucidal activity of 
hypochlorous acid solution against EHV-3 was confirmed in my laboratory. In these 
cases, it was suspected that EHV-3 was inside the vagina and that hypochlorous 
acid solution did not reach the area of infection.  
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In 2015, two Thoroughbred stallions developed ECE symptoms and EHV-3 
was isolated by penile swabs. This is the first report of EHV-3 isolation from 
stallions in Japan and administration of valacyclovir orally for treatment of ECE. 
Oral treatment with valacyclovir did not greatly shorten the duration of disease. 
The period for cure of the affected area depended on how long it took for papules 
and ulcers to heal. The affected area did not expand after administration of 
valacyclovir, and EHV-3 was susceptible to valacyclovir in vitro. Valacyclovir 
therefore seems to be effective for suppression of EHV-3 replication, but further 
investigation of the appropriate dosage of valacyclovir for treatment of ECE is 
required. At present, careful observation and washing of the vaginal area before 
mating and reducing the stress of stallions are important for prevention of ECE.  
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Table 2.1.1 Serum EHV-3 neutralizing antibody titers in EHV-3-infected 
stallions.       
Stallion  Serum Collection Dates in 2015 
 Apr. 11 Apr. 27 May 27 Jun. 30 Jul. 27 Aug. 31
A  <2 4 2 8 8 8 
   May 15 Jun. 3 Sep.16     
B  <2 2 16      
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Figure 2.1.1 Symptoms of penile area.  
(a): Stallion A on the 5th day after onset. (b): Stallion B on the 3rd day after 
onset. 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b
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Figure 2.1.2. Dose-response curves of valacyclovir (a) and acyclovir (b) for equine 
herpesvirus 3.  EC50 values are 3.0 µg/ml and 2.3 µg/ml for valacyclovir and 
acyclovir, respectively.  
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of two stallions and sero-epidemiology of EHV-3 infection in Japan 
 
2.2.1. Introduction 
ECE caused by EHV-3 is an acute, infectious, predominantly venereally 
transmitted disease as described in section 1. EHV-3 does not cause viremia and is 
non-abortigenic under natural conditions. EHV-3 showed no serologic cross-
reactivity with other equine herpesviruses in neutralization tests [6, 36, 89]. 
Recently, the complete EHV-3 genomic sequence has been reported. It has a total 
size of 151,601 nucleotides and encodes 76 distinct genes [84]. EHV-3 is highly 
host-specific and has been grown only in cells of equine origin [16]. EHV-3 is 
restricted to the epithelium of the nasal and vaginal mucosa, and the virus neither 
breaches the basement membrane nor infects individual immune cells [69]. EHV-
3 might establish a latent infection in an undefined site, from where reactivation 
and shedding might occur [2, 8, 9, 17, 90]. New outbreaks of disease might occur 
by reactivation of latent virus in clinically normal infected carrier animals [9, 90]. 
EHV-3 was first isolated in 1968 concurrently in the U.S.A., Canada, and 
Australia [15, 35, 73] and has been shown to be distributed worldwide [6]. In Japan, 
although symptoms similar to those ECE have occasionally been observed, the 
disease is obviously underdiagnosed, either because it is mild or because virological 
examinations at appropriate times are not performed. There has been only one 
report concerning isolation of EHV-3 from affected horses in Japan [81]. In this 
report, isolation of EHV-3 from two stallions described in section 1 and molecular 
characterization of the isolated viruses are described. Furthermore, by using one 
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of the isolated viruses, a sero-epidemiological survey was conducted in horses in 
Hokkaido, Japan.  
 
2.2.2. Materials and Methods 
Cell culture and virus 
For virus isolation and SN tests, FHK cells were cultured as described in 
section 1.  
 
Samples from affected horses 
For virus isolation and DNA extraction, swabs were obtained from penile 
lesions in Stallion A (case 1) at Farm A and stallion B (case 2) at Farm B as 
described in section 1.  
 
Virus isolation 
Viruses were isolated as described in section 1.  
 
DNA extraction 
DNA was extracted from virus-infected cells as previously described [38]. 
Viral DNA was extracted from the supernatant fluids of swab samples described 
above and from isolated viruses in cell-cultured fluids using a DNeasy Blood and 
Tissue kit (Qiagen K.K., Tokyo, Japan). 
 
Restriction enzyme digestion 
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The DNAs were digested to completion with restriction endonuclease 
BamHI under conditions recommended by the manufacturer (Takara Bio Inc., 
Tokyo). The digested fragments were electrophoresed through 0.7% agarose at 30 
V for 15 hr. The gels were stained with ethidium bromide (0.5 µg/ml) and visualized 
by transillumination at 302 nm [45].  
 
Polymerase chain reaction (PCR) for detection of EHV-3 
To detect EHV-3 DNA in swab samples, isolated viruses and the reference 
virus, PCR assays targeting the gG gene were carried out using Expand High 
Fidelity PCR System (Roche Diagnostics GmbH, Mannheim, Germany) and 
primers listed in Table 2.2.1 as described by Dynon et al. [27]. The PCR products 
were purified and sequenced as described below. 
 
Sequencing  
Regions coding for gB, gC, and VP13/14 and partial terminal regions of 
BamHI-A and adjacent fragments were amplified by PCR with KOD-Plus-Neo 
(Toyobo Co., LTD., Osaka, Japan) and each of the specific primers listed in Table 
2.2.1. The PCR products were purified with a High Pure PCR Product Purification 
kit (Roche Diagnostics GmbH) or with a QIAquick Gel Extraction kit (Qiagen K.K.) 
when extra bands were observed. The purified PCR products were used for 
sequencing. Sequencing was conducted in Hokkaido System Science Co., Ltd. 
(Sapporo, Japan) using the specific primers and walking primers. Sequence 
analyses were conducted by DNASIS Pro (Hitachi Software Engineering Co., Ltd, 
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Tokyo, Japan). DDBJ accession numbers assigned to the gene sequences of the 
analyzed isolates and Iwate-1 strain are LC189056-LC189067, LC189551-
LC189554 and LC199967-LC199968. 
 
Serum samples 
For a sero-epidemiological survey, sera from eight farms (A to H) in 
Hokkaido were used. Farms A and B were stud farms and the others were breeding 
farms. Sera were collected from 44 stallions in Farm A and 17 stallions in Farm B 
on April 27, 2015 and June 3, 2015, respectively. Additionally, sera were collected 
from117 mares in Farm C, 39 mares in Farm D and 30 mares in Farm E on April 
29, 2015, February 10, 2014 and January 13, 2015, respectively. Sera were also 
collected from 30 mares in Farm F, 25 mares in Farm G and 17 mares in Farm H 
on March, in 2014, January 26, 2015 and October 26, 2011, respectively. When a 
horse in Farm A or C was considered positive by serology, we used elapsed sera 
that had been stocked in my laboratory since 2002 to estimate the EHV-3 infection 
time. 
 
SN test 
Antibodies against EHV-3 in sera were determined by the SN test using 
the SS-1 isolate from stallion A as described in section 1. 
 
2.2.3. Results 
Virus isolation and identification 
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ECE was strongly suspected because of the clinical symptoms observed in 
the two affected stallions, A and B, in Farm A and Farm B, respectively [101]. 
Cytopathic effects (CPE) were observed in FHK cells after one-day post inoculation 
of penis swab samples from both stallions. CPE of both isolates were characterized 
by rounded cells and syncytial formation. The isolates from stallions A and B were 
designated as SS-1 and YS-1 strains, respectively. By PCR amplification of the 
partial gG gene of EHV-3, identical products with the same estimated size, 
approximately 520 bp, were detected from DNAs of penis swab samples of both 
stallions and isolated viruses. The nucleotide sequence identities of the amplified 
products of SS-1 and YS-1 were 99.18% and 99.80%, respectively, against that of 
the Japanese reference strain Iwate-1 and 100% and 99.39%, respectively, against 
that of full-genome sequenced Argentina isolate AR/2007/C3A (Fig. 2.2.1). BamHI 
restriction profiles revealed that SS-1 and Iwate-1 showed almost the same pattern 
(Fig. 2.2.2). A remarkable difference between SS-1 and YS-1 profiles was observed 
in the BamHI-A fragments. The BamHI-A fragment of YS-1 was larger than those 
of SS-1 and Iwate-1 by approximately 1.8 kbp. To clarify the size difference in 
BamHI-A fragments between SS-1 and YS-1, Sequence analysis was conducted on 
partial terminal regions of BamHI-A fragments. Based on the BamHI restriction 
map [92], the BamHI-A fragment consists of a unique short (Us) segment bracketed 
by a part of the inverted repeat sequences (Fig. 2.2.3). PCR primers were designed 
within the repeat sequences to amplify the estimated size of 1.2 kbp of both 
terminals of the BamHI-A fragment of YS-1. These primers could also amplify the 
same size of PCR products in SS-1. Sequence analysis of both PCR products 
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revealed that one BamHI restriction site, which was located at 958 bp from the 5’ 
end of the SS-1 PCR products, was missing in the YS-1 PCR product (Fig. 2.2.3). 
Since this site was within both inverted repeat sequences, the size difference 
between SS-1 and YS-1 BamHI-A fragments was 1,916 bp. From these results, SS-
1 and YS-1 were identified as EHV-3, but BamHI profiles of the two viruses were 
slightly different. 
 
Sequence analysis 
SS-1 and YS-1 were isolated at almost the same time in the same prefecture. 
In order to determine whether SS-1 and YS-1 were similar or not, complete 
nucleotide sequences of gB, gC and VP13/14 were determined and compared, and 
the sequences were also compared to those of Iwate-1 and Argentina isolate 
AR/2007/C3A. The gB nucleotide sequences and deduced amino acid sequences of 
SS-1, YS-1 and Argentina isolate were the same, 100% identities, but not identical 
to those of Iwate-1, 99.77% and 99.80% identities, respectively (Table 2.2.2). The 
gC nucleotide sequence and deduced amino acid sequence of SS-1 were not 
identical to those of the other three viruses, 99.79% to 99.93% identities and 
99.58% to 99.79% identities, respectively (Table 2.2.3). VP13/14 nucleotide 
sequences and deduced amino acid sequences of SS-1 and YS-1 were not identical, 
99.89% and 99.77% identities, respectively (Table 2.2.4). The results showed that 
SS-1 and YS-1 were similar isolates and also similar to Iwate-1 and Argentina 
isolate.  
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Sero-epidemiology 
To examine the prevalence of EHV-3 antibody in Japanese horses, SN tests 
using SS-1 strain and a total of 319 sera from the two stallion farms (Farms A and 
B) and six mare farms (Farms C to H) were conducted (Table 2.2.5). In Farms A 
and B, positive rates were 9.1% and 17.6%, respectively. Three of the six mare 
farms showed positive rates ranging from 2.6% to 3.4%. The positive rate for 
stallions (11.5 %) was higher than that for mares (2.3%). To estimate the EHV-3 
infection time of EHV-3 antibody-positive horses, a retrospective study was 
conducted in three stallions in Farm A and one mare in Farm C (Table 2.2.6). My 
laboratory has been stocking sera from horses in Farms A and C since 2002. 
Stallion No. 411 showed sero-conversion in June 2011 and May 2014. Stallion No. 
825 showed sero-conversion in August 2013. Stallion No. 833 showed sero-
conversion in May 2013. Mare No. 263 showed sero-conversion in May 2012. These 
four horses showed sero-conversion in the breeding season.    
 
2.2.4. Discussion 
In this study, two EHV-3 strains were isolated from separate ECE cases of 
two stallions in Japan. The BamHI DNA profile of YS-1 was almost the same of 
that of the prototype of EHV-3 [92]. Similar BamHI DNA profiles of SS-1 and 
Iwate-1 were observed in field EHV-3 isolates in Australia and the U.S.A. [13, 43]. 
The remarkable size difference observed between BamHI-A fragments of YS-1 and 
SS-1 was due to the lack of two BamHI restriction sites in YS-1, each positioned at 
958 bp from both ends of the BamHI-A fragment of YS-1. Sequence analyses of gG, 
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gB, gC and VP13/14 revealed that SS-1, YS-1 and Iwate-1 were slightly different. 
These results suggested that there might be several types of EHV-3 circulating in 
the horse population in Japan. 
Barrandeguy reported that there were at least four genetically 
distinguishable EHV-3 strains based on the partial sequence of the gG gene 
obtained from 25 field isolates [5]. Three base substitutions in the gG gene have 
been found at positions 904, 1103 and 1264, which result in strains CAT (Australia), 
AAT (U.S.A. and Brazil), CAG (Argentina) and ACT (Argentina). SS-1 belongs to 
the CAG type, and YS-1 and Iwate-1 belong to the ACT type. Therefore, in these 
criteria, Japanese EHV-3 isolates belong to the same group that Argentina isolates 
belong to, but are different from isolates of the U.S.A., Brazil and Australia. 
The sources of EHV-3 infection in the two stallions were unclear. In both 
stallion farms, the female progenital skin and mucosa were carefully observed 
before mating [101]. One possible reason was that the horse initiating the infection 
might not have shown clinical signs, and careful examination might have revealed 
one or few ulcerative lesions inside the progenital mucosa from which reactivated 
virus was shed and transmitted to the mating partner [90]. Epidemiological data 
suggested that the original viral source of an outbreak of ECE might be either a 
visiting mare brought onto the stud farm for breeding or virus reactivated from a 
member of the resident stallion or mare population [11, 17, 34, 81]. 
The sero-epidemiological study revealed that the EHV-3 positive rate was 
4.1% and that EHV-3 infection might be widespread in the horse population in 
Japan. In Argentina, almost 50% of adult, breeding-age mares were seropositive 
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and presumably latently infected [9]. In Mongolia, EHV-3 antibody-positive horses 
were detected in most provinces and the positive rate (22.9%) was higher than that 
in this study [71]. One of the reasons for this high rate might be that horse 
reproduction in Mongolia occurred through natural mating and the rate of artificial 
insemination was low. 
This study showed that the infection rate of stallions was higher than that 
of mares. This suggested that infection risk for stallions might be higher than that 
for mares due to mating with many mares. In the retrospective study, all of the 
four EHV-3 antibody-positive horses showed sero-conversion in the breeding 
season. One stallion (No. 411) showed sero-conversion against EHV-3 twice without 
any clinical symptoms of ECE. The antibody-positive period after the first sero-
conversion was only 2 months, but that after the second sero-conversion was at 
least 1 year, suggesting that reinfection or reactivation of EHV-3 might have 
occurred. Furthermore, although two other stallions (Nos. 825 and 833) in Farm A 
and 1 mare (No. 263) in Farm C showed sero-conversion against EHV-3 during the 
rearing period in each farm, no clinical case of ECE was observed. These results 
suggested that asymptomatic infection might have occurred frequently. In Japan, 
it was reported that sero-conversion against EHV-3 was observed despite no 
development of progenital regions in stallions and mares [81]. Without mating with 
a stallion, the antibody titer against EHV-3 increased in some antibody-positive 
mares [81]. These increases of the antibody titer might be due to reactivation of 
EHV-3 like other latent herpesviruses [2, 51]. Barrandeguy et al.[7, 9] reported 
that latently infected mares may not only reactivate the virus and shed it but also 
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be reinfected and shed a second virus to other horses. Viral excretion without 
clinical signs can therefore occur and contribute to the venereal and mechanical 
transmission of EHV-3. 
In conclusion, EHV-3 was firstly isolated from ECE of two stallions reared 
in different farms in Japan. The results of sero-epidemiological survey suggested 
that EHV-3 infection might exist widely without clinical symptoms in Japanese 
horses and that infection might occur mainly in the breeding season in Japan. 
 
 
 
 
 
Table 2.2.1 Primers used in PCR amplification. 
Target 
gene Primer Sequence Location 
PCR 
product 
size (bp) 
gG gG-F GCGCTCTCTCGGCCTTGCCAG 132949-132969a 518 
 gG-R GGCGTCTCGAAAAGCGAGAG 133466-133447 
gB gB-F TTCTCCTCGGTTTTCCACTG 60484-60503 3,159 
 gB-R TGTCGGATACGCGTAATGTT 63642-63623 
gC gC-F TAATCGAGATCGGCGAGTTG 20328-20347 1,531 
 gC-R GCACGAAACCCTGTTTGC 21858-21841 
VP13/14 13-F TGCGCTTTCGTCTGTGATAC 14285-14304 2,766 
 13-R GGGTAGAGGCGCACAAAAG 17050-17032 
BamHI-A A-F AAGAGGAGTGTAAGCGAAAGGA 125328-125349 1,180 
   143754-143733 1,180 
 A-R TAGCCCATCGCGTAGAAATC 126507-126488  
   142575-142594  
a. Location at the complete nucleotide sequence of EHV-3 strain AR/2007/C3A 
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(Genbank NC_024771.1).  
 
 
 
 
  
83 
 
Table 2.2.2 Identities of nucleotide sequence and amino acid sequence of gB among 
EHV-3 isolates.  
a. EHV-3 isolate from case 1.  
b. EHV-3 isolate from case 2. 
c. EHV-3 isolate from Iwate prefecture [81]. 
d. Argentina isolate (KM051845.1). 
  
 
 
 
 
 
 
 
 
 
 
 
Table 2.2.3 Identities of nucleotide sequence and amino acid sequence of gC among 
Identity (%) of nucleotide sequence (2,982 bp) 
 
SS-1 YS-1 Iwate-1 AR/2007/C3A 
SS-1a 100.00 99.77 100.00 
YS-1b 100.00 99.77 100.00 
Iwate-1c 99.80 99.80 99.77 
AR/2007/C3Ad 100.00 100.00 99.77 
 Identity (%) of amino acid sequence (994 aa) 
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EHV-3 isolates. 
Identity (%) of nucleotide sequence (1,419 bp)
 
SS-1 YS-1 Iwate-1 AR/2007/C3A 
SS-1a 99.93 99.79 99.79 
YS-1b 99.79 99.86 99.86 
Iwate-1c 99.58 99.79 99.72 
AR/2007/C3Ad 99.79 100.00 99.79 
 
Identity (%) of amino acid sequence (473 aa)
a. EHV-3 isolate from case 1.  
b. EHV-3 isolate from case 2. 
c. EHV-3 isolate from Iwate prefecture [81]. 
d. Argentina isolate (KM051845.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2.4 Identities of nucleotide sequence and amino acid sequence of  
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VP13/VP14 among EHV-3 isolates. 
Identity (%) of nucleotide sequence (2,658 bp) 
 
SS-1 YS-1 Iwate-1 AR/2007/C3A 
SS-1a 99.89 99.81 99.92 
YS-1b 99.77 99.85 99.81 
Iwate-1c 99.66 99.89 99.74 
AR/2007/C3Ad 100.00 99.77 99.66 
 
 Identity (%) of amino acid sequence (886 aa)
a. EHV-3 isolate from case 1.  
b. EHV-3 isolate from case 2. 
c. EHV-3 isolate from Iwate prefecture [81]. 
d. Argentina isolate (KM051845.1).  
 
 
  
86 
 
Table 2.2.5 Prevalence of EHV-3 neutralizing antibody in horses in Hokkaido in 
Japan. 
 
Farm    Category    Collecting date  Positive sera/tested sera   
A Stallion 27 Apr. 2015       4a (4 - 16)b/44(9.1)c  
B Stallion 3 Jun. 2015        3d (2-16) /17(17.6) 
C Broodmare 29 Apr. 2015        4 (2 - 8) /117(3.4) 
D Broodmare 10 Feb. 2014            1 (4) /39(2.6) 
E Broodmare 13 Jan. 2015                 0/30(0) 
F Broodmare 11 Mar. 2014             1(8)/30(3.3) 
G Broodmare 26 Jan. 2015                 0/25(0) 
H Broodmare 26 Oct. 2011                 0/17(0)  
Subtotal Stallion -                     7/61(11.5) 
 Broodmare -                     6/258(2.3)  
Total                       13/319(4.1) 
a. One positive serum is from stallion A. 
b. Numbers in parenthesis are the range of EHV-3 neutralizing antibody-positive 
titers 
c. Number in parenthesis is positive percent.  
d. One positive serum is from stallion B. 
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Table 2.2.6. Retrospective study of EHV-3 neutralizing antibody positive-horses in 
Farms A and C. 
Farm Horse 
No. 
Neutralizing antibody titer 
A 411 
(♂, 
23y)c 
02a ’07 ’08 ’09 ’10 ’11 ’12 ’13 ’14 
  
’15
7b 7 7 7 10 5 6 7 8 6 6 4 5 7 12 4
-d - - - - - 8 2 - - - - 32 16 8 16
825 
(♂, 8y) 
’10 ’11 ’12 ’13 ’14 ’15
   
10 7 10 6 7 8 9 12 4
   
- - - - - 4 4 8 4
   
833 
(♂, 10y) 
’11 ’12 ’13 ’14 ’15
7 10 4 5 6 12 4
- - - 32 16 8 16
C 263 
(♀, 14y) 
’07 ’08 ’11 ’12 ’13 ’15
6 7 12 4 5 6 9 4
- - - - 8 4 2 2
a. Year, b. Month, c. Inside of parenthesis shows gender and age (years old), d) -: 
<2 
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Figure 2.2.1 Comparison of nucleotide sequences of the partial gG gene from two 
field strains (SS-1 and YS-1) with those of Japanese reference strain Iwate-1 and 
Argentina AR/2007/C3A strains.  
 The identical nucleotide is indicated by a dot. Numbers on the left and right 
sides are the nucleotide position of the EHV-3 gG gene.  
 
 
 
Iw ate-1 813 GGGCCCTCAATCCCTGCTCA TTGGCGCCCTGGGACTTCGC ATCCTGAGCCAGCGCTGGTA CATGCTGCCGGGCGAGACGT ACGACCAGCT 902
SS-1 813 .................... .................... .................... ...............A.... .......... 902
YS-1 813 .................... .................... .................... ...............A.... .......... 902
AR /2007
/C 3A
813 .................... .................... .................... ...............A.... .......... 902
Iw ate-1 903 GAGGCAAAATTCCAGAGGGT CTGCCCGCGGCGCAGACAGG GAATCCGCGGCCGACGTAAC AGAACCCGAAGAAAAGCCTT CGGAAAAAAC 992
SS-1 903 .C.................. .................... .................... .................... .......... 992
YS-1 903 .................... .................... .................... .................... .......... 992
AR /2007
/C 3A
903 .C.................. .................... .................... .................... .......... 992
Iw ate-1 993 CCCCGCTTCTCCCACCGATG ACGAGGAGAAAGAAGAAGAG GAAAACGGGGATAACGAGCC AACCCCAGCGCCACCGGCCC CGGGATGCGA 1082
SS-1 993 .................... .................... .................... .................... .......... 1082
YS-1 993 .................... .................... .................... .................... .......... 1082
AR /2007
/C 3A
993 .................... .................... .................... .................... .......... 1082
Iw ate-1 1083 CGAGCAAGACGCACCTGCCG CCGGAGACGGATCTCCGTGG TACACCGGCGGCATTCTCGT GTCCGGTCCTGAGTGCGGAC AGCAGAAGGG 1172
SS-1 1083 .................... A................... .................... .................... .......... 1172
YS-1 1083 .................... .................... .................... .................... .......... 1172
AR /2007
/C 3A
1083 .................... A................... .................... .................... .......... 1172
Iw ate-1 1173 GACCAACTACGCGGGTATCG GCTTTCTCATCTTGGGAGTG TGTCTCCTCATCGGCCTCAT TGTCTACGTTTGCGTCCTGC GGTCCAGAGT 1262
SS-1 1173 .................... .................... .................... .................... .......... 1262
YS-1 1173 .................... .................... .................... .................... .......... 1262
AR /2007
/C 3A
1173 .................... .................... .................... .................... .......... 1262
Iw ate-1 1263 CTCCGAGCGCAAGCTCCACA ACAGCTACTCTCGCTTTT 1300
SS-1 1262 .G.................. .................. 1300
YS-1 1262 .................... .................. 1300
AR /2007
/C 3A
1263 .G.................. .................. 1300
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Figure 2.2.2 BamHI restriction profiles of DNAs of SS-1 and YS-1 strains and 
Japanese reference strain Iwate-1.  
Lane 1: molecular weight marker, lambda DNA Hind III digest, Lane 2: 
Iwate-1, Lane 3: SS-1, Lane 4: YS-1.  
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Fig. 2.2.3 BamHI partial restriction map of SS-1 and YS-1 strains.  
The map was based on Sullivans et al. [92]. Internal repeat (IR) and 
terminal repeat (TR) are indicated by open boxes. Extra BamHI sites observed in 
SS-1 are indicated by open triangles.    
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Summary 
In this dissertation, equine herpesvirus 3 (EHV-3) was isolated from 2 
stallions. It was the first report of isolation of EHV-3 from stallions in Japan.  
In order to evaluate the efficiency of valacyclovir, an anti-herpesvirus agent, 
2 stallions were administered valacyclovir orally. It was suggested that 
valacyclovir was effective to suppress EHV-3, however, it did not shorten the time 
until the symptoms were cure. The dosage regimen used in this study seemed to 
result in a plasma concentration that did not exceed the 50% effective 
concentration (EC50) value of EHV-3.  
EHV-3 isolates from 2 stallions and Iwate prefecture were not the same type 
by sequence analysis.  
In sero-epidemiology study, EHV-3 positive rate was 4.1% in Japan. Positive 
rate in stallions (11.5%) was higher than that of mares (2.3%). Sero-conversion 
against EHV-3 was observed in breeding season without any clinical symptoms of 
equine coital exanthema (ECE). Reinfection or reactivation of EHV-3 might occur 
in breeding season.  
 
 
 
 
 
CONCLUSION 
First, the present study confirmed that chemiluminescent enzyme 
92 
 
immunoassay (CLEIA) system is an effective tool for measurement of progesterone 
(P), estradiol (E) and testosterone (T) concentrations in clinical cases in horses. 
Further, the CLEIA system has an advantage that it allows the use of whole blood. 
Rapid measurement of P concentrations by CLEIA system is helpful to diagnose 
the estrus condition of mares coming to stud for mating. Measurement of E 
concentrations by CLEIA system is expected to be a help for rapid diagnosis of 
placental abnormalities. Measurement of T concentration by CLEIA system is 
helpful to diagnose reproductive abnormalities by human chorionic gonadotrophin 
(hCG) challenge test or gonadotropin releasing hormone (GnRH) challenge test. 
The rapidity of CLEIA system in T measurement is also valuable especially for 
monitoring T concentrations in stallions treated with T product for low libido. 
Second, the present study described two cases of equine coital exanthema 
(ECE) and a sero-epidemiological study. An anti-herpesvirus agent, valacyclovir, 
was found to suppress viral multiplication in vitro, however, treatment with 
valacyclovir failed to improve clinical outcomes, probably due to improper timing 
of administration or insufficient dosage. Sero-epidemiological study revealed that 
equine herpesvirus 3 (EHV-3) infection exists without clinical signs in Japan. The 
antibody prevalence rate against EHV-3 was higher in stallions than mares and it 
is suggested that infection risk for stallions is higher because stallions may have 
an increased chance of mating with affected mares. Careful observation of external 
genitalis and penile area is needed in studs to prevent spreading this disease.  
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